Bulgarian drug maker Sopharma said on Monday that its sales revenue fell by an annual 4% in the first quarter of 2020, due to a 6% decrease in sales on foreign markets. In March alone, Sopharma’s sales rose 11% due to a 21% jump in exports, the company said in a bourse filing. The company did not disclose information about the volume of its sales or amount of sales revenue. As at 12:30 CET on Monday, Sopharma shares traded at 2.42% higher at 2.96 levs ($1.63/1.51 euro) on the Bulgarian Stock Exchange.
